INFORME PUBLICITÁRIO ANVISA ACHIEVED GREAT ADVANCEMENTS TO THE HEALTH OF BRAZILIAN PATIENTS The Brazilian Health Surveillance Agency (ANVISA) becomes the first regulatory agency in the Southern Hemisphere to integrate the Management Committee of the International Council for Harmonization (ICH), a forum that brings together world authorities that define the alignment of health regulations for medicines and the pharmaceutical industry. As a member of this important Committee, ANVISA is in line with the Brazilian Federal Government’s agenda raising the countries standards and aligning with prime-markets, promoting the harmonization of the regulatory framework to international standards, boosting trade between countries and promoting economic growth, as well as broadening concrete possibilities for Brazil ascensions to International Forums and organizations. This effort will bring more investments, jobs, income and relevant innovations for health in Brazil. For the Regulatory Agency, it means giving voice to the country in defining international rules for medicines and pharmaceutical research. It puts Brazil in the same level of discussion for regulations of the United States, the European Union, Japan, Canada, Switzerland, South Korea, China and Singapore, ICH’s member nations. We congratulate ANVISA’s technical team and its professionals for the modern and results-focused agenda and the continuous seek for regulatory convergence, aligning global standards while maintaining ANVISA’s regulatory independence. ANVISA’s performance at ICH will translate into greater access to modern therapies and faster drug registration. An important step for Health in Brazil. This initiative brings hope and new perspectives to thousands of Brazilian patients.